Showing posts with label Patient compliance. Show all posts
Showing posts with label Patient compliance. Show all posts

Friday, August 27, 2010

Combination product approved for some hypertension patients

A combination product for hypertention was recently approved by the FDA. Tribenzor, the three-in-one product, uses other hypertention drugs olmesartan medoxomil, hydrochlorothiazide, and amlodipine to relax blood vessels and allows blood to flow more freely. This combination product hopes to help those with hypertension by simplifying pill regiments, reduce the number of pills a patient takes and lower co-pay for the pills. It is hoped that this combination product will allow more individuals to reach their goal for their best blood pressure. Modern Medicine has more on the new combination product.




Share this article with your social network, just click below to share now!


Wednesday, January 27, 2010

DDP 2010: Technology Showcase Spotlight Session: Move Beyond Passive to Active Transdermal Drug Delivery Technology- Progress on the Janisys Microneed

John O'Dea, PhD, CEO, Janisys

Pump vs Patch
Pump:
-Control of timing
-Any liquid formation
-Blousing
-Large

Patch:
-Convenience
-Ease of use
-Small/discrete
-Limited formulations

When using this patch, the history of drug delivery can be recorded, and most drugs can be put on the patch. The value proposition lies in having a lot of different drugs available. There is 85-90% efficiency of drug projection.


Share this article with your social network, just click below to share now!


Wednesday, January 20, 2010

2010 DDP Awards: Pipeline Value Creation Nominee: Centric Health Resources

Value Creation: Direct distribution model to leverage opportunities for cost-effective drug delivery and personalized health management services

Centric Health Resources is a new generation, Patient-Centered Health Management® organization, serving patients with rare, orphan, and ultra-orphan disorders. Centric has a deep understanding of the value of personalized relationships, helping biotech and pharmaceutical manufacturers to better serve this targeted market niche, which is typically defined as relatively small patient populations of less than 10,000.

Centric pioneered the direct distribution model, which virtually eliminates the costs and resources associated with multiple touch points for getting the specialty product into the hands of the patient. As a result, the price of the drug remains transparent and stable, without unnecessary mark-ups that inflate costs for patients and payers. Attractive pricing reflects efficiencies associated with integration as well as lower overhead. The Centric approach allows biopharmaceutical manufacturers to leverage opportunities for cost-effective drug delivery and personalized health management services. This distinctive model improves patient compliance with therapy, drives better outcomes, and provides additional long-term support for patients and their caregivers. It also offers the opportunity for pharmaceutical companies to demonstrate value to patients, physicians and payers, adapt to a changing regulatory environment, and raise support from the patient community by engaging patient advocacy groups as partners in the provision of services.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.


Share this article with your social network, just click below to share now!